-
Mashup Score: 4Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial - 7 month(s) ago
Abstract Background Tafolecimab is a novel fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody, developed for the treatment of hypercholesterolemia. Objectives The…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0LDL-C Reduction With Lipid-Lowering Therapy for Older Individuals - American College of Cardiology - 7 month(s) ago
Melvyn Rubenfire, MD, FACC
Source: www.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Is there a difference in clinical effectiveness of lowering LDL-C w/ lipid-lowering therapy for primary prevention of #CVD among older & younger individuals? Find out the answer here: https://t.co/RsnJojdpza #cvLipids https://t.co/U7K4gPM6CU
-
-
Mashup Score: 3High-Throughput Microscopy Characterization of Rare LDLR Variants: - 7 month(s) ago
Highlights • Around 40% of LDLR variants are classified as VUS, posing as the biggest hurdle to reach a definitive FH diagnosis. • We optimized and validated a time- and cost-effective high-through…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
Interesting study by Dr. Rafael Graça et al. on the use of a high-throughput cell-based assay to functionally profile LDL receptor variants of unknown significance. https://t.co/e7wJafY6Lz #JACCBTS #cvLipids #LDLR #CardioTwitter https://t.co/HWd25BZjwA
-
-
Mashup Score: 2Treatment of ATTR Amyloidosis - American College of Cardiology - 12 month(s) ago
A 76-year-old man with a medical history of hypertension, hyperlipidemia, type 2 diabetes mellitus, carpal tunnel syndrome, and benign prostatic hypertrophy was recently diagnosed with wildtype transthyretin (ATTR) cardiac amyloidosis with preserved left ventricular ejection fraction of 51% on echocardiography. He does not have a known history of atrial fibrillation or coronary artery disease. He…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A 76 y/o man with a history of #Hypertension, #cvLipids, #Diabetes, carpal tunnel syndrome & benign prostatic hypertrophy was diagnosed with ATTR cardiac amyloidosis. Which medications could be considered for the patient’s treatment? Vote here: https://t.co/bcIaNm1zfp #ACCEd
-
-
Mashup Score: 31Heart Failure Fact or Fiction: BP, How Low Is Too Low? - American College of Cardiology - 12 month(s) ago
A 71-year-old man with heart failure with reduced ejection fraction (HFrEF; 30%) due to ischemic cardiomyopathy, hypertension, and hyperlipidemia is admitted for acute decompensated heart failure (HF). He received 3 days of intravenous furosemide and optimization of guideline-directed medical therapy (GDMT). He is now euvolemic. He reports dizziness with ambulation this morning during bedside…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A 71 y/o man with #HFrEF due to ischemic cardiomyopathy, #Hypertension & #cvLipids is admitted for acute decompensated #HeartFailure. What is the best next step in the patient’s treatment? Test your knowledge with this patient case quiz: https://t.co/nAFGgLvVpQ #ACCEd
-
-
Mashup Score: 2Heart Failure Fact or Fiction: Creatinine's Cautionary Tale - American College of Cardiology - 12 month(s) ago
A 68-year-old woman with heart failure with reduced ejection fraction (HFrEF; left ventricular ejection fraction 35%), hypertension, hyperlipidemia, and stable chronic kidney disease (CKD) is seen in the clinic 2 weeks after admission for acute decompensated heart failure (HF), for which she required several days of intravenous diuresis. She was discharged on her previous medications: metoprolol…
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A 68 y/o woman with #HFrEF, #Hypertension, #cvLipids & stable chronic kidney disease is seen in the clinic 2 weeks after admission for acute decompensated #HeartFailure. What is the clinician’s next step in her treatment? Get the details and vote here: https://t.co/oIsaoBN1oR
-
-
Mashup Score: 6
We are grateful to these distinguished Members of the American College of Cardiology who contributed to this collection: Martha Gulati, MD, MS, FACC (Chair) Christie M. Ballantyne, MD, FACC Anum Saeed, MD Salim S. Virani, MD, FACC Karol E. Watson, MD, FACC
Source: learn.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Apply your knowledge to patient case scenarios & learn to develop an evidence-based treatment plan that includes ensuring optimization of statin & non-statin therapies to ⬇️ ASCVD risk w/ certified patient cases on #cvLipids management. More: 🔗 https://t.co/GPDTQxM9HT #ACCEd https://t.co/ysJrjBAMZL
-
-
Mashup Score: 3Exertional Shortness of Breath - American College of Cardiology - 1 year(s) ago
The patient is a 70-year-old male with a history of diabetes mellitus type I, hypertension, hyperlipidemia, anemia, paroxysmal atrial fibrillation, and s/p atrial flutter ablation 6 months ago. He presents with dyspnea on exertion, pedal edema, and weight gain. An electrocardiogram (ECG) (Figure 1) is performed. Figure 1
Source: American College of CardiologyCategories: Cardiology News and Journals, Latest HeadlinesTweet-
A 70 y/o male w/ a history of #diabetes, #hypertension, #cvLipids, anemia, paroxysmal #AFib & s/p atrial flutter ablation presents w/ dyspnea on exertion, pedal edema & weight gain. What does the patient’s #EKG show? Vote here: https://t.co/3YEr3cqPnu #ACCEd https://t.co/K7UP2byGtY
-
-
Mashup Score: 0
We are grateful to these distinguished Members of the American College of Cardiology who contributed to this collection: Martha Gulati, MD, MS, FACC (Chair) Christie M. Ballantyne, MD, FACC Anum Saeed, MD Salim S. Virani, MD, FACC Karol E. Watson, MD, FACC
Source: learn.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Apply your knowledge to patient case scenarios & learn to develop an evidence-based treatment plan that includes ensuring optimization of statin & non-statin therapies to ⬇️ ASCVD risk w/ ACC’s Clinical Spotlight Series. 🔗 https://t.co/JPNiTbKV4K #NYCVS #ACCEd #cvLipids https://t.co/ii6Q2wPFWC
-
-
Mashup Score: 1
We are grateful to these distinguished Members of the American College of Cardiology who contributed to this collection: Martha Gulati, MD, MS, FACC (Chair) Christie M. Ballantyne, MD, FACC Anum Saeed, MD Salim S. Virani, MD, FACC Karol E. Watson, MD, FACC
Source: learn.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
🆕 Certified Patient Cases on Lipid Management Test your knowledge & earn up to 0.5 CME/CNE credits & MOC points w/ 2️⃣ new certified patient cases as part of ACC’s Clinical Spotlight Series, “Modern Lipid Management.” Learn more: 🔗 https://t.co/GPDTQxM9HT #ACCEd #cvLipids https://t.co/oJgGG7jB3n
-
In Chinese patients at high or very high #CVD risk with ⬆️ #cvLipids, #tafolecimab was safe and showed lipid-lowering efficacy. https://t.co/TizJPDW34Q 🎧: https://t.co/Iu9aesyWNr #JACCAsia #cvCAD #Hypercholesterolemia #CardioTwitter #JACCPodcast https://t.co/8JNER67ZRB